Pfizer Inc. may have to convince an advisory committee and FDA officials not to wait another year for a post-marketing trial to be completed before considering taking a boxed warning for severe neuropsychiatric events out of the Chantix label.
Data from a meta-analysis of several trials as well as observational studies that the company submitted in a labeling supplement for the smoking cessation drug was judged insufficient to justify...